First Merchants Corp Buys 745 Shares of Zoetis Inc. $ZTS

First Merchants Corp grew its stake in Zoetis Inc. (NYSE:ZTS) by 2.9% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 26,547 shares of the company’s stock after purchasing an additional 745 shares during the quarter. First Merchants Corp’s holdings in Zoetis were worth $4,140,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of ZTS. Nuveen LLC bought a new position in shares of Zoetis in the 1st quarter worth about $616,375,000. Mackenzie Financial Corp increased its stake in shares of Zoetis by 4,158.3% in the 1st quarter. Mackenzie Financial Corp now owns 1,824,967 shares of the company’s stock worth $300,481,000 after acquiring an additional 1,782,110 shares in the last quarter. Polen Capital Management LLC increased its stake in shares of Zoetis by 17.6% in the 1st quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company’s stock worth $1,448,401,000 after acquiring an additional 1,313,653 shares in the last quarter. Amundi increased its stake in shares of Zoetis by 30.8% in the 1st quarter. Amundi now owns 3,595,628 shares of the company’s stock worth $575,691,000 after acquiring an additional 846,909 shares in the last quarter. Finally, OVERSEA CHINESE BANKING Corp Ltd increased its stake in shares of Zoetis by 475.9% in the 1st quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 900,261 shares of the company’s stock worth $148,228,000 after acquiring an additional 743,926 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors.

Zoetis Stock Performance

Shares of ZTS stock opened at $143.61 on Thursday. The company has a 50 day moving average price of $149.41 and a 200-day moving average price of $154.74. Zoetis Inc. has a 52 week low of $139.34 and a 52 week high of $196.55. The firm has a market capitalization of $63.65 billion, a PE ratio of 24.72, a P/E/G ratio of 2.29 and a beta of 0.90. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, topping analysts’ consensus estimates of $1.62 by $0.14. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The firm had revenue of $2.46 billion during the quarter, compared to analyst estimates of $2.41 billion. During the same period in the previous year, the business posted $1.56 earnings per share. The business’s revenue for the quarter was up 4.2% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, equities research analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the stock. Argus reiterated a “buy” rating and issued a $190.00 price target on shares of Zoetis in a research note on Tuesday, September 9th. Piper Sandler raised their price objective on shares of Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a research note on Monday, August 11th. Leerink Partners lowered shares of Zoetis from an “outperform” rating to a “market perform” rating and reduced their price objective for the company from $180.00 to $155.00 in a research note on Thursday, July 17th. Stifel Nicolaus lowered shares of Zoetis from a “buy” rating to a “hold” rating and reduced their price objective for the company from $165.00 to $160.00 in a research note on Wednesday, June 18th. Finally, Leerink Partnrs lowered shares of Zoetis from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 17th. Five equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat.com, Zoetis has an average rating of “Moderate Buy” and an average target price of $200.88.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.